EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Short Interest Update

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) saw a significant growth in short interest in December. As of December 31st, there was short interest totalling 10,340,000 shares, a growth of 9.9% from the December 15th total of 9,410,000 shares. Based on an average daily volume of 956,300 shares, the short-interest ratio is currently 10.8 days.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on EYPT. Citigroup began coverage on EyePoint Pharmaceuticals in a research report on Tuesday, January 7th. They issued a “buy” rating and a $33.00 target price for the company. Scotiabank started coverage on EyePoint Pharmaceuticals in a research note on Wednesday, October 16th. They set a “sector outperform” rating and a $18.00 target price on the stock. Chardan Capital upped their target price on EyePoint Pharmaceuticals from $28.00 to $33.00 and gave the company a “buy” rating in a report on Friday, November 8th. Robert W. Baird lowered their price objective on shares of EyePoint Pharmaceuticals from $38.00 to $33.00 and set an “outperform” rating on the stock in a research report on Monday, November 11th. Finally, HC Wainwright reiterated a “buy” rating and issued a $22.00 price objective on shares of EyePoint Pharmaceuticals in a research note on Thursday, December 5th. One equities research analyst has rated the stock with a sell rating and ten have given a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $26.63.

EyePoint Pharmaceuticals Stock Up 2.9 %

Shares of EYPT traded up $0.21 during mid-day trading on Monday, hitting $7.48. 564,887 shares of the company’s stock were exchanged, compared to its average volume of 778,205. EyePoint Pharmaceuticals has a twelve month low of $6.90 and a twelve month high of $30.99. The firm has a fifty day moving average of $8.40 and a two-hundred day moving average of $8.96. The stock has a market cap of $510.51 million, a price-to-earnings ratio of -3.74 and a beta of 1.49.

Hedge Funds Weigh In On EyePoint Pharmaceuticals

Several institutional investors have recently bought and sold shares of EYPT. China Universal Asset Management Co. Ltd. boosted its stake in shares of EyePoint Pharmaceuticals by 68.2% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 10,293 shares of the company’s stock worth $82,000 after acquiring an additional 4,172 shares in the last quarter. Greenwich Wealth Management LLC boosted its position in EyePoint Pharmaceuticals by 8.3% during the third quarter. Greenwich Wealth Management LLC now owns 11,700 shares of the company’s stock worth $93,000 after purchasing an additional 900 shares during the period. Cyndeo Wealth Partners LLC acquired a new position in EyePoint Pharmaceuticals during the third quarter valued at approximately $100,000. Intech Investment Management LLC bought a new position in shares of EyePoint Pharmaceuticals in the third quarter valued at approximately $136,000. Finally, GSA Capital Partners LLP lifted its stake in shares of EyePoint Pharmaceuticals by 129.6% in the third quarter. GSA Capital Partners LLP now owns 32,979 shares of the company’s stock worth $264,000 after buying an additional 18,616 shares during the last quarter. 99.41% of the stock is currently owned by institutional investors.

About EyePoint Pharmaceuticals

EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.